SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Facade of Moderna's building in Massachusetts
Earnings
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.
November 7, 2024
 · 
3 min read
 · 
Tristan Manalac
Check mate. hand of businessman moving chess figure Trendy 3d collage in magazine style. Contemporary art. Modern design
GLP-1
While Lilly Blames Wholesalers for Slow GLP-1 Sales, Novo’s Rival Medicine Is Flowing
Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week. But Eli Lilly reported slower than expected sales in the third quarter due to wholesaler destocking.
November 7, 2024
 · 
3 min read
 · 
Annalee Armstrong
Courtesy of Sarepta Therapeutics
Earnings
Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales
The investigational therapy, vesleteplirsen, had been positioned as an updated version of Sarepta’s original exon 51-skipping Duchenne muscular dystrophy drug Exondys 51.
November 7, 2024
 · 
2 min read
 · 
Heather McKenzie
Business
Investing in AI: Benefits, Regulatory Challenges
In this episode of Denatured, BioSpace’s Head of Insights Lori and guests from Teva Pharmaceuticals and TOWER Capital discuss the opportunities, regulatory challenges and uncertainty surrounding AI.
November 7, 2024
 · 
1 min read
 · 
Lori Ellis
Whitchurch-Stouffville, On, Canada: - May 30, 2021: Teva Canada Ltd facility in Whitchurch-Stouffville, On, Canada. Teva Pharmaceutical Industries Ltd. is an Israeli pharmaceutical company.
Earnings
Teva Reports Strong Generics Demand in Q3, Expects Higher 2024 Revenue
Driven by copycat versions of Bristol Myers Squibb’s Revlimid and Novo Nordisk’s Victoza, Teva’s generics business was again a top-performer in the third quarter, with U.S. sales growing 30% and bringing in $1.1 billion in sales.
November 7, 2024
 · 
2 min read
 · 
Tristan Manalac
Gilead sign at headquarters. FDA will reportedly authorize use of remdesivir developed by biopharmaceutical company Gilead Sciences for Covid-19 treatment - Foster City, California, USA - 2020
Earnings
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and “steady,” while noting the company continues to demonstrate “reliable strength” in its human immunodeficiency virus business.
November 7, 2024
 · 
3 min read
 · 
Tristan Manalac
Job Trends
2024 Q3 Job Market Report: Biopharma Professionals Face Heavy Competition for Fewer Jobs
Year-over-year BioSpace data shows there are fewer job postings live on the website and far more competition for them.
November 7, 2024
 · 
3 min read
 · 
Angela Gabriel
Facade of Novo Nordisk's office in Fremont, California
Earnings
Novo Misses Overall Q3 Revenue Despite Beating Wegovy Sales Forecast, Narrows 2024 Outlook
Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year guidance for revenue and operating profit.
November 6, 2024
 · 
3 min read
 · 
Tristan Manalac
Donald Trump behind a podium
Policy
Trump Victory a ‘Modest Positive’ for Biopharma Industry: Analysts
Analyst reactions to Donald Trump’s election victory were mixed Wednesday, with potential positives including an FTC that is likely to be more friendly to M&A, and negatives including concerns about what role Robert F. Kennedy, Jr. might play in healthcare.
November 6, 2024
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS